Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by stock analysts at Leerink Swann from an “underperform” rating to a “market perform” rating in a report released on Monday. The firm presently has a $50.00 price target on the stock. Leerink Swann’s price objective would indicate a potential downside of 10.28% from the company’s current price.

SRPT has been the subject of a number of other reports. Royal Bank Of Canada upgraded shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 price target for the company in a research report on Monday. Vetr lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $17.28 price target for the company. in a research report on Monday, May 23rd. Robert W. Baird reiterated an “outperform” rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, July 26th. Finally, JMP Securities reiterated an “underperform” rating and issued a $10.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $51.01.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.8060% during mid-day trading on Monday, hitting $56.1792. 5,016,233 shares of the company traded hands. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $58.87. The stock’s market capitalization is $2.69 billion. The firm’s 50 day moving average price is $28.17 and its 200-day moving average price is $21.37.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the company posted ($0.87) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.98) EPS for the current year.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 10.90% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp increased its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc bought a new position in Sarepta Therapeutics during the second quarter valued at approximately $302,000. National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the period. 72.09% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.